An early cancer detection test is a medical assessment that helps to identify the risks of cancer in apparently healthy people. A person with cancer may, or may not, be experiencing significant symptoms; moreover, the presence of symptoms alone is not a reliable indicator to confirm having cancer. Under this situation, an early cancer detection test can tell the likeliness of having such disease at the test moment or in the future. With the information provided by an early cancer detection test, a patient can realise the disease earlier and receive timely treatment. The patient might possibly suffer fewer complications and experience better survival. An early cancer detection test with high sensitivity and specificity can further reduce the possibilities of misdiagnosis and lift the anxiety brought by inaccurate testing results.

The Take2 Prophecy™ Test for NPC is an early cancer detection test which is suitable for anyone, no matter one is asymptomatic or with non-specific symptoms. Our test is blood-based and non-invasive with the use of ground-breaking Next-generation Sequencing technology to analyse human and NPC-associated genomic signatures of EBV DNA in the blood plasma. By testing early, NPC patients can be identified at the early stage then start to receive treatment much earlier which can minimise possible side-effects and significantly increase their chance of survival.

Through promoting early cancer detection, we are dedicated to helping the public to understand cancer and the available detection solutions, hence establishing higher awareness and better management of personal health in the community. By adopting the cutting-edge medical innovations, it is now able to envision a brighter future with advanced healthcare management.